CL2004001278A1 - COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN - Google Patents

COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN

Info

Publication number
CL2004001278A1
CL2004001278A1 CL200401278A CL2004001278A CL2004001278A1 CL 2004001278 A1 CL2004001278 A1 CL 2004001278A1 CL 200401278 A CL200401278 A CL 200401278A CL 2004001278 A CL2004001278 A CL 2004001278A CL 2004001278 A1 CL2004001278 A1 CL 2004001278A1
Authority
CL
Chile
Prior art keywords
oxybin
fluoruracilo
etopocido
cisplatino
camptotecina
Prior art date
Application number
CL200401278A
Other languages
English (en)
Spanish (es)
Inventor
Osamu Sugawara Tatsu Nakanishi
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CL2004001278A1 publication Critical patent/CL2004001278A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200401278A 2003-05-26 2004-05-26 COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN CL2004001278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
CL2004001278A1 true CL2004001278A1 (es) 2005-05-06

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401278A CL2004001278A1 (es) 2003-05-26 2004-05-26 COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN

Country Status (27)

Country Link
US (1) US20070098816A1 (https=)
EP (1) EP1626719A1 (https=)
JP (1) JP2006526031A (https=)
KR (1) KR100938712B1 (https=)
CN (2) CN1794991A (https=)
AR (1) AR045318A1 (https=)
AU (1) AU2004241873C1 (https=)
BR (1) BRPI0410959A (https=)
CA (4) CA2634766A1 (https=)
CL (1) CL2004001278A1 (https=)
CO (1) CO5660262A2 (https=)
CR (1) CR8163A (https=)
CU (1) CU23490B7 (https=)
EC (1) ECSP056253A (https=)
IL (1) IL171941A0 (https=)
ME (1) MEP32308A (https=)
MX (1) MXPA05012345A (https=)
NO (1) NO20055417L (https=)
NZ (1) NZ543591A (https=)
PE (1) PE20050206A1 (https=)
RS (1) RS20050884A (https=)
RU (1) RU2322971C2 (https=)
TW (1) TW200505424A (https=)
UA (1) UA81499C2 (https=)
UY (1) UY28330A1 (https=)
WO (1) WO2004103369A1 (https=)
ZA (1) ZA200509515B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007095584A2 (en) 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US9408816B2 (en) * 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PT2350005E (pt) * 2008-08-29 2012-03-12 Bayer Pharma AG Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
EP2395972A4 (en) * 2009-02-11 2014-02-12 Liangping Yu PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
RU2011142806A (ru) * 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EP3103452A1 (en) * 2009-08-25 2016-12-14 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
JP6330118B2 (ja) 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CN108685922A (zh) * 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
EP3194387B1 (en) 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
MEP32308A (en) 2010-10-10
PE20050206A1 (es) 2005-03-26
CA2634766A1 (en) 2004-12-02
AU2004241873C1 (en) 2009-01-22
KR20060009371A (ko) 2006-01-31
TW200505424A (en) 2005-02-16
RU2322971C2 (ru) 2008-04-27
ECSP056253A (es) 2006-10-25
NO20055417D0 (no) 2005-11-16
CN1794991A (zh) 2006-06-28
UA81499C2 (en) 2008-01-10
KR100938712B1 (ko) 2010-01-25
MXPA05012345A (es) 2006-02-08
US20070098816A1 (en) 2007-05-03
EP1626719A1 (en) 2006-02-22
RS20050884A (sr) 2008-04-04
AU2004241873A1 (en) 2004-12-02
AU2004241873B8 (en) 2008-05-29
IL171941A0 (en) 2006-04-10
RU2005140570A (ru) 2006-06-10
BRPI0410959A (pt) 2006-07-04
ZA200509515B (en) 2006-07-26
CA2634709A1 (en) 2004-12-02
WO2004103369A1 (en) 2004-12-02
CU23490B7 (es) 2010-02-23
CA2527191A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
UY28330A1 (es) 2004-12-31
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
JP2006526031A (ja) 2006-11-16
CA2634765A1 (en) 2004-12-02
AR045318A1 (es) 2005-10-26
AU2004241873B2 (en) 2008-05-08
NO20055417L (no) 2005-12-19
NZ543591A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
CL2004001278A1 (es) COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN
FR17C1028I2 (fr) Médicaments anticancéreux contenant de la alpha, alpha, alpha-trifluorothymidine et un inhibiteur de la thymidine phosphorylase
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
ES2527409T4 (es) Formulaciones de inhibidores de DPP IV
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
NL1030486A1 (nl) Dibenzylamineverbindingen en derivaten.
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
DK2057153T3 (da) (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
CL2007002686A1 (es) Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular.
BRPI0721213A2 (pt) "regime de dosagem de inibidores da comt"
NL2000527A1 (nl) Dibenzylamine-verbindingen en -derivaten.
NO20051688D0 (no) Farmasoytiske blandinger som har en modifisert baerer
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0608885A2 (pt) composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica
DK1587478T3 (da) Farmaceutisk sammensætning
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem
EP1869031A4 (en) THIADIAZOL SUBSTITUTED CUMARINE DERIVATIVES AND THEIR USE AS LEUKOTRIEN BIOSYNTHESIS INHIBITORS
CL2008000463A1 (es) Compuestos derivados de benzofuranos sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar infecciones parasitarias.
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.